A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Biotechnology Computer Science Energy Engineering Environmental Sciences Information Science Life Sciences Mathematics Medical Sciences

Military Sciences Natural Sciences Physical Sciences Plant Sciences Science Space Sciences Technology Transportation